Abercrombie & Fitch

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to August 1, 2026: $5.34 billion, up 4.7% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to August 1, 2026: $0.57 billion, up 68% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to August 1, 2026: $0.25 billion, up 14% from a year earlier.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to January 31, 2026: $0.45 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (August 26, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
• Guidance in the last 90 days: 5 outlook figures raised, 1 lowered, 1 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed March 26, 2026): 1 risk factor added, 3 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $10.6 million on the open market.SEC Form 4
• 413 institutional managers reported a position at June 30, 2026 (+3 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 14 (9 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Abercrombie & Fitch yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)third_quarter 2026 · $0.0 million
2. Oct 20, 2026Patent
   Patent granted: SYSTEM AND METHOD FOR OSTOMY INFORMATION COLLECTION AND ANALYSISUS 12766027
3. Oct 7, 2026Lobbying
   Lobbying report (HOLLAND & KNIGHT LLP)third_quarter 2026 · $0.0 million
4. Sep 22, 2026Patent
   Patent granted: OSTOMY APPLIANCE AND FILTER ASSEMBLY WITH BYPASS VENTINGUS 12740887
5. Sep 15, 2026Patent
   Patent granted: OSTOMY FILTERUS 12734062
6. Aug 20, 20268-K
   Director or officer changeItem 5.02
7. Aug 11, 2026Patent
   Patent granted: REUSABLE URINARY CATHETER KITSUS 12702790
8. Aug 11, 2026Patent
   Patent granted: REDUCED-SPILL HYDROPHILIC CATHETER PRODUCT WITH FOAMED HYDRATION LIQUIDUS 12702791
9. Jul 14, 2026Lobbying
   Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)second_quarter 2026 · $0.0 million
10. Jul 14, 2026Lobbying
    Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)first_quarter 2026 · $0.0 million
11. Jul 13, 2026Lobbying
    Lobbying report (HOLLAND & KNIGHT LLP)second_quarter 2026 · $0.0 million
12. Jun 4, 20268-K
    Shareholder vote resultsItem 5.07
13. May 15, 2026Lobbying
    Lobbying report (HOLLAND & KNIGHT LLP)second_quarter 2026
14. Apr 20, 2026Lobbying
    Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)first_quarter 2026 · $0.0 million
15. Mar 26, 202610-K
    Annual report (10-K)1 risk factors added, 3 removed
16. Jan 20, 2026Lobbying
    Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)fourth_quarter 2025 · $0.0 million
17. Dec 15, 20258-K
    Director or officer changeItem 5.02
18. Jun 12, 20258-K
    Shareholder vote resultsItem 5.07
19. Mar 31, 202510-K
    Annual report (10-K)1 risk factors added, 0 removed
20. Nov 26, 20248-K
    Director or officer changeItem 5.02
21. Nov 21, 20248-K
    Director or officer changeItem 5.02
22. Apr 1, 202410-K
    Annual report (10-K)4 risk factors added, 2 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1018840

LEI

5493000J7LL72TOGT983

Wikidata

Q319344